drugset / Trial / NCT05009966
Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid Tumor
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, dose escalation, dose expansion and extension cohort phase 1 study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of SYSA1801
Timeline
- Start
- 2021-09-16
- Primary completion
- 2023-12
- Completion
- 2024-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SYSA1801 | Unknown | 0.5 mg/kg | Intravenous |
| Subject | SYSA1801 | Unknown | 1 mg/kg | Intravenous |
| Subject | SYSA1801 | Unknown | 2 mg/kg | Intravenous |
| Subject | SYSA1801 | Unknown | 3 mg/kg | Intravenous |
| Subject | SYSA1801 | Unknown | 4.5 mg/kg | Intravenous |
| Subject | SYSA1801 | Unknown | 6 mg/kg | Intravenous |